NASDAQ · EWTX
Edgewise Therapeutics, Inc.
$38.91-$1.58 (-3.9%)
Edgewise Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.79% below the high.
Loading market information…
NASDAQ · CNTA · USD
Stock price, earnings
Quote as of Jun 25, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Centessa Pharmaceuticals plc’s quoted price sits in the upper half of its reported 52-week range, 0.15% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Centessa Pharmaceuticals plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.37+11.9% vs estimate |
| $0.00 |
| Q2 2024 | Aug 13, 2024 | -$0.40-5.26% vs estimate | $0.00 |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$38.91-$1.58 (-3.9%)
Edgewise Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.79% below the high.
$20.76-$0.31 (-1.47%)
NewAmsterdam Pharma Company N.V.’s quoted price sits in the lower half of its reported 52-week range, 50.82% below the high.
$15.45-$0.11 (-0.71%)
Cullinan Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.38% below the high.
$10.87+$0.02 (+0.18%)
Monte Rosa Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.82% below the high.
$11.06-$0.02 (-0.18%)
Design Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.88% below the high.
$1.46-$0.04 (-2.67%)
Century Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.97% below the high.
$3.73+$0.02 (+0.54%)
Inventiva S.A.’s quoted price sits in the lower half of its reported 52-week range, 48.83% below the high.
$0.76-$0.00 (-0.54%)
Compass Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.01% below the high.
